The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Hepatotoxicity associated with statins
Abstract
Treatment with statins is known all over the world. They are generally considered safe at therapeutic doses. Nevertheless, clinical trials are not enough to assess their scarce adverse effects such as idiosyncratic drug induced liver injury (DILI). Due to some conditions, such as concomitant usage (drug-drug interaction using an identical metabolising enzyme) and genetic polymorphisms, there is an increasing concern about their safety. Hepatotoxicity and rhabdomyolysis have begun to appear in published studies. Most of investigations have focused on both these adverse effects and mechanisms of drug induced toxicity. The present review has attempted to compile almost all of the existing studies on the hepatotoxicity of statins but not rhabdomyolysis. The aim of our study is to provide an overview of the studies on the statin-associated hepatotoxicity and to discuss the published studies. The researchers are of the opinion that the research on this topic is incomplete but extremely necessary.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The overall incidence rate for statin-induced acute liver failure (ALF) has been reported to be between 1 and 2 per 100,000 person-years.2,5”
From Atorvastatin-Induced Liver Injury With Concurrent Rhabdomyolysis After a Positive Rechallenge (2025) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227
Early indicators of prognosis in fulminant hepatic failure
O'Grady, J. G., Alexander, G. J. M., Hayllar, K. M., & Williams, R. (1989) · Gastroenterology · doi:10.1016/0016-5085(89)90081-4 · Cited by 2,085
Risk Factors for Idiosyncratic Drug-Induced Liver Injury
Chalasani, N., & Björnsson, E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.001 · Cited by 347 · cited 1×
“Simvastatin is metabolised primarily by CYP3A4, when it is used concomitantly with amiodarone, which is an inhibitor of CYP3A4 enzyme; and interaction between these two drugs (simvastatin and amiodarone) increases hepatotoxicity (42).”
BackgroundIdiosyncratic drug-induced liver injury: an overview
Hussaini, S. H., & Farrington, E. A. (2007) · Expert Opinion on Drug Safety · doi:10.1517/14740338.6.6.673 · Cited by 183
Lipid-lowering agents that cause drug-induced hepatotoxicity.
Bhardwaj, S. S., & Chalasani, N. (2007) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.06.010 · Cited by 173 · cited 1×
“in guinea pigs caused necrosis in hepatic cells (21).”
Background
Research works printed but not linked: 48
- 1. Bjørneboe M, Iversen O, Olsen S. Infective hepatitis and toxic jaundice in a municipal hospital during a five-year period: incidence and prognosis. Acta Med Scand 1967;182:491-501. doi: 10.1111/j.0954-6820.1967.tb10873.x · DOI
- 2. Malchow-Møller A, Matzen P, Bjerregaard B, Hilden J, Holst-Christensen J, Staehr JT, Altman L, Thomsen C, Juhl E. Causes and characteristics of 500 consecutive causes of jaundice. Scand J Gastroenterol 1981;16:1-6. PMID: 7233075
- 3. Whitehead MW, Hainsworth I, Kingham JG. The causes of obvious jaundice in South West Wales: perceptions versus reality. Gut 2001;48:409-13. doi: 10.1136/gut.48.3.409 · DOI
- 4. Björnsson E, Ismael S, Nejdet S, Kilander A. Severe jaundice in Sweden in the new millennium: causes, investigations, treatment and prognosis. Scand J Gastroenterol 2003;38:86-94. doi: 10.1080/00365520310000492 · DOI
- 6. Williams R. Classification, etiology, and considerations of outcome in acute liver failure. Semin Liver Dis 1996;16:343-8. doi: 10.1055/s-2007-1007247 · DOI · Paper page
- 9. Hoofnagle JH, Carithers RL Jr, Shapiro C, Nascher H. Fulminant hepatic failure: summary of a workshop. Hepatology 1995;21:240-52. doi: 10.1016/0270- 9139(95)90434-4 · doi:10.1016/0270-
- 10. Bakke OM, Manocchia M, de Abajo F, Kaitin KI, Lasagna L. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Clin Pharm Therap 1995;58:108-17. doi: 10.1016/0009-9236(95)90078-0 · DOI · Paper page
- 11. Zimmerman HJ. Drug-induced liver disease. Clin Liver Dis 2000;4:73-96. PMID: 11232192 · DOI · Paper page
- 12. Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975;69:289-302. PMID: 1150039 · DOI · Paper page
- 14. Zimmerman HJ. Drug-induced liver disease. In: Sciff ER, Sorrell MF, Maddrey WC, editors. Sciff′s diseases of the liver. 8th edition. Philadelphia: Lippincott-Raven Publishers; 1999. p. 973-1064.
- 15. Pillans PI. Drug associated hepatic reactions in New Zealand: 21-years’ experience. N Z Med J 1996;109:315-9. PMID: 8816722
- 16. Friis H, Andreasen PB. Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987. J Intern Med 1992;232:133-8. doi: 10.1111/j.1365-2796.1992.tb00562.x · DOI
- 17. Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008;8:373-418. doi: 10.2165/0129784-200808060-0000 · doi:10.2165/0129784-200808060-0000
- 18. Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005;42:481-9. doi: 10.1002/hep.20800 · DOI · Paper page
- 19. Kshirsagar A, Vetal Y, Ashok P, Bhosle P, Ingawale D. Drug induced hepatotoxicity: a comprehensive review. Internet J Pharmacol 2008 [displayed 18 October 2017]. Available at http://ispub.com/IJPHARM/7/1/3723 · doi:10.5580/2b8
- 20. Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol 2006;97(Suppl 1):77C-81C. doi: 10.1016/j.amjcard.2005.12.014 · DOI · Paper page
- 22. Kubota T, Fujisaki K, Itoh Y, Yano T, Sendo T, Oishi R. Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors. Biochem Pharmacol 2004;67:2175-86. doi: 10.1016/j.bcp.2004.02.037 · DOI
- 23. Wolters LMM, Van Buuren HR. Rosuvastatin-associated hepatitis with autoimmune features. Eur J Gastroenterol Hepatol 2005;17:589-90. PMID: 15827453 · DOI
- 24. Russo MW, Hoofnagle JH, Gu J, Fontana RJ, Barnhart H, Kleiner DE, Chalasani N, Bonkovsky HL. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepat 2014;60:679-86. doi: 10.1002/hep.27157 · DOI · Paper page
- 25. Kubatka P, Kruzliak P, Rotrekl V, Jelinkova S, Mladosievicova B. Statins in oncological research: from experimental studies to clinical practice. Crit Rev Oncol Hematol 2014;92:296-311. doi: 10.1016/j.critrevonc.2014.08.002 · DOI
- 26. Cueto R, Valdivielso P, Lucena MI, Garcίa-Arias C, Andrade RJ, Gonzάlez-Santos P. Statins: hepatic disease and hepatotoxicity risk. Open Gastroenterol J 2008;2:18-23. doi: 10.2174/1874259900802010018 · DOI
- 27. Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepat 2005;41:690-5. doi: 10.1002/hep.20671 · DOI · Paper page
- 28. Thapar M, Russo MW, Bonkovsky HL. Statins and liver injury. Gastroenterol Hepatol 2013;9:605-6. PMCID: PMC3983981
- 29. Abdoli N, Azarmi Y, Eghbal MA. Protective effects of N-acetylcysteine against the statins cytotoxicity in freshly isolated rat hepatocytes. Adv Pharm Bull 2014;4:249-54. doi: 10.5681/apb.2014.036 · DOI
- 30. Tolosa L, Carmona A, Castell JV, Gόmez-Lechόn MJ, Donato MT. High-content screening of drug-induced mitocondrial impairment in hepatic cells: effects of statins. Arch Toxicol 2015;89:1847-60. doi: 10.1007/s00204-014-1334-3 · DOI
- 31. Ciba M, Ak M, Karahalil B. Alpha-glutathione-s-transferase can be a biomarker for both drug-related toxicity as well as individual susceptibility. Minerva Psichiatr 2016;57:62-71.
- 32. Abdoli N, Heidari R, Azarmi Y, Eghbal MA. Mechanism of the statins cytotoicity in freshly isolated rat hepatocytes. J Biochem Molecular Toxicol 2013;27:287-94. doi: 10.1002/ jbt21485 · DOI
- 33. Haque T, Sasatomi E, Hayashi PH. Drug-induced liver injury: Pattern recognition and future directions. Gut Liver 2016;10:27-36. doi: 10.5009/gnl15114 · DOI
- 34. Fitchett DH, Hegele RA, Verma S. Cardiology patient page. Statin intolerance. Circulation 2015;131:e389-91. doi: 10.1161/CIRCULATIONAHA.114.013189 · DOI
- 35. Wang LY, Huang Y, Perng C, Huang B, Lin H. Statin-induced liver injury in an area endemic for hepatitis B virus infection: risk factors and outcome analysis. Br J Clin Pharmacol 2016;82:823-30. doi: 10.1111/bcp.13009 · DOI
- 36. de Denus S, Spinler SA, Miller K, Peterson AM. Statins and liver toxicity: a meta-analysis. Pharmacotherapy 2004;24:584-91. doi: 10.1592/phco.24.6.584.34738 · DOI · Paper page
- 37. Bradford RH, Shear CL, Achanassios N, Chremos AN, Dujovne C, Downton M, Franklin FA, Gould AL, Hesney M, Higgins J, Hurley DP, Langendorfer A, Nash DT, Pool JL, Schnaper H. Expanded clinical evaluation of lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991;151:43-9. doi: 10.1001/archinte.1991.00400010067008 · DOI · Paper page
- 38. Roberts WC. Getting more people on statins. Am J Cardiol 2002;90:683-5. doi: 10.1016/S0002-9149(02)02590-0 · doi:10.1016/s0002-9149(02)02590-0
- 39. Tolman KG. The liver and lovastatin. Am J Cardiol 2002;89:1374-80. doi: 10.1016/S0002-9149(02)02355-X · DOI · Paper page
- 40. Kirchheiner J, Kudlicz D, Meisel C, Bauer S, Meineke I, Roots I, Brockmöller J. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterollowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin Pharmacol Ther 2003;74:186-94. doi: 10.1016/S0009-9236(03)00121-8 · DOI
- 41. Flockhart DA, Rae JM. Cytochrome P450 3A pharmacogenetics: the road that needs traveled. Pharmacogenom J 2003;3:3-5. doi: 10.1038/sj.tpj.6500144 · doi:10.1038/sj.tpj.6500144
- 43. Zhong G, Liu Y, Ye Y, Hao F, Wang K, Gong J. Meta-analysis of studies using statins as a reducer for primary liver cancer risk. Sci Rep 2016;26256-65. doi: 10.1038/srep26256 · DOI
- 44. Licata A, Minissale MG, Calvaruso V, Craxì A. A focus on epidemiology of drug-induced liver injury: analysis of a prospective cohort. Eur Rev Med Pharmacol Sci 2017;21(Suppl 1):112-21. PMID: 28379588
- 45. Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol 2012;56:374-80. doi: 10.1016/j. jhep.2011.07.023 · doi:10.1016/j
- 46. Leise MD, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. Mayo Clin Proc 2014;89:95-106. doi: 10.1016/j. mayocp.2013.09.016 · doi:10.1016/j
- 47. Raschi E, Poluzzi E, Koci A, Salvo F, Pariente A, Biselli M, Moretti U, Moore N, De Ponti F. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system. Br J Clin Pharmacol 2015;80:285-93. doi: 10.1111/bcp.12611 · DOI
- 48. Björnsson ES. Drug-induced liver injury: an overview over the most critical compounds. Arch Toxicol 2015;89:327-34. doi: 10.1007/s00204-015-1456-2 · DOI
- 49. Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis 2009;29:412-22. doi: 10.1055/s-0029-1240010 · DOI · Paper page
- 50. Charles EC, Olson KL, Sandhoff BG, McClure DL, Merenich JA. Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. Am J Med 2005;118:618-24. doi: 10.1016/j.amjmed.2005.02.008 · DOI
- 51. Perdices EV, Medina-Cáliz I, Hernando S, Ortega A, Martín- Ocaña F, Navarro JM, Peláez G, Castiella A, Hallal H, Romero-Gómez M, González-Jiménez A, Robles-Díaz M, Lucena MI, Andrade RJ. Hepatotoxicity associated with statin use: analysis of the cases included in the Spanish Hepatotoxicity Registry. Rev Esp Enferm Dig 2014;106:246-54. PMID: 25075655
- 52. Chang CH, Chang YC, Lee YC, Liu YC, Chuang LM, Lin JW. Severe hepatic injury associated with different statins in patients with chronic liver disease: a nationwide population- based cohort study. J Gastroenterol Hepatol 2015;30:155-62. doi: 10.1111/jgh.12657 · DOI
- 53. Younoszai Z, Li Z, Stepanova M, Erario M, Cable R, Younossi ZM. Statin use is not associated with liver related mortality. Ann Hepatol 2014;13:84-90. doi: 10.1007/s11274- 015-1903-5 · doi:10.1007/s11274-
- 54. Rangnekar AS, Fontana RJ. An update on drug induced liver injury. Minerva Gastroenterol Dietol 2011;57:213-29. PMID: 21587150
Cited by
Atorvastatin-Induced Liver Injury With Concurrent Rhabdomyolysis After a Positive Rechallenge
Singh, H., Khalaf, A., Kunkle, B. F., Gholami, S., Lewis, J. H., & Rangnekar, A. S. (2025) · ACG Case Reports Journal · doi:10.14309/crj.0000000000001570 · Cited by 3
Metadata
- Authors
- Karahalil, B., Hare, E., Koç, G., Uslu, İ., Şentürk, K., & Özkan, Y.
- Affiliations
- Toxicology Department, Faculty of Pharmacy, Gazi University Ankara, Ankara , Turkey
- Venue
- Archives of Industrial Hygiene and Toxicology
- Publisher
- Walter de Gruyter GmbH
- Published
- 2017-12-20
- Volume
- 68
- Issue
- 4
- Pages
- 254-260
- ISSN
- 0004-1254
- Cited by
- 41
- References
- 5
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hepatotoxicity associated with statins. https://app.cochat.ai/papers/10.1515/aiht-2017-68-2994
- The paper
- Karahalil, B., Hare, E., Koç, G., Uslu, İ., Şentürk, K., & Özkan, Y. (2017). Hepatotoxicity associated with statins. Archives of Industrial Hygiene and Toxicology. https://doi.org/10.1515/aiht-2017-68-2994
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

